Alan M. Miller

1.6k total citations
34 papers, 546 citations indexed

About

Alan M. Miller is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Alan M. Miller has authored 34 papers receiving a total of 546 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Hematology and 6 papers in Molecular Biology. Recurrent topics in Alan M. Miller's work include Hematopoietic Stem Cell Transplantation (5 papers), Neutropenia and Cancer Infections (5 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (3 papers). Alan M. Miller is often cited by papers focused on Hematopoietic Stem Cell Transplantation (5 papers), Neutropenia and Cancer Infections (5 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (3 papers). Alan M. Miller collaborates with scholars based in United States, Australia and Canada. Alan M. Miller's co-authors include A. A. Yunis, Grace K. Arimura, Adel A. Yunis, Ziad Salem, Thomas M. Grogan, Thomas P. Miller, Richard I. Fisher, Patrick J. Stiff, Leo I. Gordon and Michael LeBlanc and has published in prestigious journals such as Nature, Journal of Clinical Investigation and Blood.

In The Last Decade

Alan M. Miller

33 papers receiving 514 citations

Peers

Countries citing papers authored by Alan M. Miller

Since Specialization

Citations

This map shows the geographic impact of Alan M. Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan M. Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan M. Miller more than expected).

Fields of papers citing papers by Alan M. Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan M. Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan M. Miller. The network helps show where Alan M. Miller may publish in the future.

Co-authorship network of co-authors of Alan M. Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Alan M. Miller. A scholar is included among the top collaborators of Alan M. Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan M. Miller. Alan M. Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	WATCHMAN COMPLICATIONS REPORTED IN THE MANUFACTURER AND USER FACILITY DEVICE EXPERIENCE DATABASE 2019 ·Journal of the American College of Cardiology ·(unknown), (unknown), Alan M. Miller, (unknown), Antony Chu	1
2	Takotsubo Cariomyopathy Secondary to Theophylline Toxicity: Old Drug With New Side Effect 2015 ·CHEST Journal ·(unknown), Amit Gupta, (unknown), Alan M. Miller	0
3	Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome 2014 ·Bone Marrow Transplantation ·Mary Jo Lechowicz, Hillard M. Lazarus, Joaquim Carreras, Ginna G. Laport, Corey Cutler, Peter H. Wiernik, Gregory A. Hale, Dipnarine Maharaj, Robert Peter Gale, Philip A. Rowlings, César O. Freytes, Alan M. Miller, Julie M. Vose, Richard T. Maziarz, Silvia Montoto, DG Maloney, Parameswaran Hari	64
4	Acute Myelogenous Leukemia at Baylor Charles A. Sammons Cancer Center, 2010 to 2012: Retrospective Analysis of Molecular Genetic Evaluation 2014 ·Baylor University Medical Center Proceedings ·Catherine Jones, (unknown), Alan M. Miller	1
5	Model for the Cost-Efficient Delivery of Continuous Quality Cancer Care: A Hospital and Private-Practice Collaboration 2013 ·Baylor University Medical Center Proceedings ·Yvonne M. Coyle, Alan M. Miller, (unknown)	10
6	Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder 2008 ·Transplantation ·Lode J. Swinnen, Michael LeBlanc, Thomas M. Grogan, Leo I. Gordon, Patrick J. Stiff, Alan M. Miller, Yvette L. Kasamon, Thomas P. Miller, Richard I. Fisher	82
7	Neuronal Stem Cells Biology and Plasticity 2003 ·Cancer Investigation ·Vincent F. La Russa, Debasis Mondal, Alan M. Miller, Hana Safah, Marta Rozans, Tyler J. Curiel, Krishna C. Agrawal, Roy S. Weiner	1
8	Marrow Stem Cells, Mesenchymal Progenitor Cells, and Stromal Progeny 2002 ·Cancer Investigation ·Vincent F. La Russa, Paul Schwarzenberger, Alan M. Miller, Krishna C. Agrawal, Jay K. Kolls, Roy S. Weiner	15
9	Decreased Quality of Peripheral Blood Progenitors Collected After a Peripheral Blood Progenitor Transplant 2000 ·Journal of Hematotherapy & Stem Cell Research ·Alan M. Miller, David G. Morrison, Hana Safah, (unknown), Vincent F. LaRussa, (unknown), Roy S. Weiner	1
10	Use of PEG-rHuMGDF in platelet engraftment after autologous stem cell transplantation 2000 ·Bone Marrow Transplantation ·(unknown), Michael Crump, Isabelle Bence‐Bruckler, Steven H. Bernstein, Stephanie Williams, Stanley Frankel, Alan M. Miller, George D. Demetri, (unknown), Scott Cruickshank, Michael Lill	7
11	Limited erythropoietic response to combined treatment with recombinant human interleukin 3 and erythropoietin in myelodysplastic syndrome 1999 ·Leukemia Research ·Alan M. Miller, (unknown), Raymond Taetle, Alan F. List	15
12	Exacerbation of bleomycin-induced lung injury in mice by amifostine 1999 ·American Journal of Physiology-Lung Cellular and Molecular Physiology ·Luis A. Ortiz, Joseph A. Lasky, Hana Safah, (unknown), Alan M. Miller, Giuseppe Lungarella, Mitchell Friedman	9
13	Durable remission of locally advanced breast cancer with multimodality management 1998 ·Medical Oncology ·Alan M. Miller, Ajit Khosla, James Lynch, Jan S. Moreb, (unknown), Hana Safah, C. Hutchison, Vincent La Russa, (unknown), James Rice, Nancy P. Mendenhall, Roy S. Weiner	2
14	Toxicity associated with high-dose cytosine arabinoside and total body irradiation as conditioning for allogeneic bone marrow transplantation 1997 ·Bone Marrow Transplantation ·(unknown), (unknown), (unknown), (unknown), (unknown), Alan M. Miller, John Graham‐Pole	11
15	Frequency ofBCL-2/JH translocations in peripheral blood of follicular lymphoma patients 1997 ·American Journal of Hematology ·(unknown), Hana Safah, Raja Mudad, (unknown), John R. Krause, Alan M. Miller, Melanie Ehrlich	1
16	Lipoxygenase metabolism is required for interleukin-3 dependent proliferation and cell cycle progression of the human M-07e cell line 1997 ·Journal of Cellular Physiology ·Alan M. Miller, (unknown), Vincent A. Ziboh	7
17	Improved survival of patients with chronic myelogenous leukemia undergoing allogeneic bone marrow transplantation 1995 ·American Journal of Hematology ·Jan S. Moreb, Thomas M. Johnson, Paul Kubilis, (unknown), (unknown), Alan M. Miller, Gerald J. Elfenbein, Roy S. Weiner	6
18	Dietary fish oil supplementation alters LTB4:LTB5 ratios but does not affect the expression of acute graft versus host disease in mice 1993 ·Prostaglandins Leukotrienes and Essential Fatty Acids ·Alan M. Miller, D.W. van Bekkum, (unknown), (unknown), Shoshan Knaän‐Shanzer	14
19	Lymphoreticular cells isolated by centrifugal elutriation from a mammary adenocaricinoma. i. characterization of an in situ lymphocyte suppressor population by surface markers and functional reactivity 1984 ·International Journal of Cancer ·(unknown), (unknown), Alan M. Miller, Diana M. Lopez	12
20	The lobotomy patient--a decade later: a follow-up study of a research project started in 1948. 1967 ·PubMed ·Alan M. Miller	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact